Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS) -- Ignore unavailable to you. Want to Upgrade?

To: DSPetry who wrote (3698)	7/27/1999 9:40:00 AM
From: G.P.	Read Replies (2) \| Respond to of 4028

***NEWS*** Tuesday July 27, 8:03 am Eastern Time Company Press Release CYGS Confirms Compounder Connection Antisense Apothecaries Link MD with R&D HOUSTON--(BUSINESS WIRE)--July 27, 1999--Cryogenic Solutions Inc. (OTC BB:CYGS) is cultivating relationships in the compounding pharmaceutical industry which will position the company to provide its patented antisense delivery technology to compounding pharmacists as a constituent for the preparation of novel antisense gene therapy drugs prescribed by physicians for individual patients. The early apothecaries were chemists and herbalists who mixed and combined their ingredients one prescription at a time. Today, although most neighborhood pharmacies are actually retail outlets for mass produced medications, there remain thousands compounding pharmacists who customize drugs for prescribing physicians and their patients. Historically, compounding pharmacists were primarily involved with combining various chemicals into products that mostly provide symptomatic relief or temporary control of physical ailments. Today however, breakthroughs in molecular biology provide for a paradigm shift in the design and synthesis of drugs. Recently, biomedical research and development has generated genetically based therapies with the ability to permanently correct some medical conditions at the cellular level. Additionally, the technological protocols, apparatus, and equipment are readily available which enable a compounding pharmacist to fill prescriptions for compounds including naturally occurring biological components like DNA. The Texas Pharmacy Act defines ''compounding'' as the preparation, mixing, and assembling of a drug or device based on the physician-patient-pharmacist relationship in the course of professional practice. The purpose of the act is to promote, preserve, and protect the public health, safety, and welfare through effective control of the practice of pharmacy. Current regulations provide latitude for the compounding of customized molecular biology products on an individual prescription basis. The company's research indicates most states similarly define this activity. CYGS is specifically focused on the application of compounded pharmaceuticals for antisense molecules. Dozens of biotech companies have collectively identified and patented several hundred oligodeoxyribonucleotides (ODN's) that have demonstrated therapeutic potential in the laboratories. These promising therapeutic molecules have not made their way into mainstream medicine because of the difficulties encountered in trying to ''deliver'' the ODN's into the cells of living humans or animals (in vivo expression). This ''delivery barrier'' problem is described more fully in the company's prior public releases and on its website at cygs.net. The CYGS single stranded DNA intracellular expression vector (ssDNA IEV) overcomes this ''delivery barrier'' to in vivo expression of antisense ODN's. CYGS is working with the Professional Compounding Centers of America, Inc. of Houston, Texas, a leading compounding pharmaceutical supplier with a network of more than 2,500 pharmacists. This collaboration will enable compounding pharmacists to upgrade their knowledge and equipment to effectively participate in this promising new biomedical technology. The company anticipates that increasing numbers of physicians will begin prescribing specific ODN's to genetically correct specific medical conditions. The compounding pharmacist will combine the prescribed molecule with the CYGS vector to deliver and initiate synthesis of the ODN in the nucleus of the targeted cells. Once in the cells the antisense ODN can neutralize the mRNA and disrupt production of harmful proteins, effectively eliminating the disease at the cellular level. Compounding is an effective entry point into the healthcare system for the delivery of antisense therapies. There is a growing population of physicians with solid background knowledge of molecular biology and of specific antisense ODN's. The missing elements have been a viable delivery system and pharmacists who could fill the prescription. The delivery system is our ssDNA expression vector and we're moving to fill the prescription void through compounding pharmacies with expanded capabilities. The near term goal is to create an environment in which a physician can prescribe a customized antisense ODN compound and the patient can have that prescription filled, possibly even via the internet. Treatment of disease in the 21st century will look very different than it does today. The purpose of this CYGS release is to clarify its pursuits of compounding pharmaceutical relationships and prevent any misunderstanding or rumor that may result from such activities. This release contains forward-looking statements and is made under the protections afforded by the Securities Litigation Reform Act of 1995. Anyone who does not understand the overall antisense biotechnology referenced in this document or the significance of the specific CYGS technology is discouraged from investing in this company. -------------------------------------------------------------------------------- Contact: Cryogenic Solutions Inc., Houston Dell Gibson, 713/780-1399